NCT00302341View on ClinicalTrials.gov

DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)

PHASE3TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Pneumonia, Interstitial Plasma CellPneumocystis Carinii PneumoniaPneumonia, Pneumocystis CariniiHIV Infections
Interventions
DRUG

Pafuramidine maleate (DB289)

Oral tablet, 100 mg bid, 14 days

DRUG

Trimethoprim-Sulfamethoxazole (TMP-SMX)

15 mg/kg, oral tablet split tid X 21 days

Trial Locations (7)

10016

NYU School of Medicine, New York

29425

Medical University of SC, Charleston

48202

Henry Ford Health System, Detroit

60637

The University of Chicago, Chicago

94110

University of California, San Francisco

27599-7030

UNC AIDS Clinical Trials, Chapel Hill

45267-0405

University of Cincinnati, Cincinnati

Sponsors
All Listed Sponsors
lead

Immtech Pharmaceuticals, Inc

INDUSTRY